- Drug development company Evgen Pharma said it had enrolled and dosed its first patient in the STAR trial evaluating SFX-01 as a treatment for acute respiratory infections.

This phase II/III trial would investigate whether the Company's lead asset, SFX-01, 'can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for suspected COVID-19,' the company said.

'We remain hopeful that the outcome of this trial will reduce both the severity and duration of the disease for COVID-19 patients and those with pneumonia from other infective agents,' it added.

At 9:47am: [LON:EVG] Evgen Pharma Plc share price was 0p at 8.3p

Story provided by